MENU

BNTX Stock BioNTech SE American Depositary Share (BNTX, $113.52) Moving Average Convergence Divergence (MACD) Histogram turned positive on August 15, 2025

A.I.dvisor
at Tickeron.com
Loading...
BNTX - BioNTech SE American Depositary Share
MACD signal
Bullish Trend
Odds of UP Trend
Tickeron
MACD signal
Price: $113.52
Daily change: +$0.82 (+0.73%)
Daily volume: 501.4K
Capitalization: $27.3B
Industry: Biotechnology
This is a Bullish indicator signaling BNTX's price could rise from here. Traders may explore going long the stock or buying call options. A.I. dvisor identified 43 similar cases where BNTX's MACD histogram became positive, and of them led to successful outcomes. Odds of Success:

BNTX's RSI Oscillator leaves overbought zone

The 10-day RSI Oscillator for BNTX moved out of overbought territory on July 14, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 instances where the indicator moved out of the overbought zone. In of the 25 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BNTX broke above its upper Bollinger Band on July 23, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 13, 2025. You may want to consider a long position or call options on BNTX as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for BNTX just turned positive on August 15, 2025. Looking at past instances where BNTX's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

BNTX moved above its 50-day moving average on August 04, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BNTX advanced for three days, in of 284 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 157 cases where BNTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.259) is normal, around the industry mean (19.433). P/E Ratio (161.759) is within average values for comparable stocks, (50.965). BNTX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.945). Dividend Yield (0.000) settles around the average of (0.042) among similar stocks. P/S Ratio (8.104) is also within normal values, averaging (301.042).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BNTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

View a ticker or compare two or three
BNTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. BNTX showed earnings on August 04, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a company, which focuses on the development of molecular immune therapies and biomarker-based diagnostic approaches

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
An der Goldgrube 12
Phone
+49 613190840
Employees
6133
Web
https://www.biontech.de